Business Context and Reporting Period
The Chemours Company filed a Form 8-K on September 20, 2019, announcing a strategic decision to exit its Methylamines and Methylamides business located at its Belle, West Virginia facility. The company targets stopping production at this site in November 2019, with remediation and dismantlement activities planned to commence in 2020 and last approximately one year.
Key Financial Metrics
The filing details specific financial impacts related to the exit plan rather than full-period consolidated results.
- Total Pre-tax Charges: Approximately $43 million.
- Non-cash Impairment Charges: Approximately $30 million related to property, plant, and equipment.
- Cash Expenditures: Approximately $13 million, broken down as follows:
- $4 million for severance and other employee costs.
- $8 million for decommissioning, dismantling, and removal costs.
- $1 million for other termination-related costs.
- Historical Performance (2018): The exiting business contributed $125 million in Net Sales and negative EBITDA of $3.5 million.
Material Changes and Timing
The primary material change is the recognition of a $43 million pre-tax charge. The company expects to incur all non-cash impairment charges and severance costs in the remainder of 2019. The remaining cash charges related to decommissioning and removal are expected to be incurred during 2020. The Belle site will continue operations for other products within the Fluoroproducts and Chemical Solutions businesses.
Outlook, Risks, and Management Commentary
Management intends to work with all Methylamines and Methylamides customers during the transition period. The filing includes standard forward-looking statements regarding financial performance, business plans, and cost estimates, noting that actual results may differ materially due to risks and uncertainties. The company assumes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the timing of the $30 million non-cash impairment charge in the Q3 2019 earnings release.
- Confirm the impact of the $4 million severance cost on Q3 2019 cash flow.
- Monitor the 2020 capital expenditure budget for the estimated $8 million in decommissioning costs.
- Assess the impact of the $125 million sales reduction on future revenue guidance.
- Review the status of customer transition agreements for the Methylamines and Methylamides lines.